{"id":65563,"date":"2026-05-18T14:50:34","date_gmt":"2026-05-18T06:50:34","guid":{"rendered":"https:\/\/flcube.com\/?p=65563"},"modified":"2026-05-18T14:50:35","modified_gmt":"2026-05-18T06:50:35","slug":"allogene-therapeutics-terminates-asian-car-t-joint-venture-with-overland-pharmaceuticals-strategic-retreat-from-allogeneic-cell-therapy-market-in-asia","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65563","title":{"rendered":"Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals \u2013 Strategic Retreat from Allogeneic Cell Therapy Market in Asia"},"content":{"rendered":"\n<p><strong>Allogene Therapeutics, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ALLO:NASDAQ\">NASDAQ: ALLO<\/a>) announced the <strong>termination of its strategic collaboration<\/strong> with <strong>Overland Pharmaceuticals<\/strong> on cell therapy development across key Asian markets, effective <strong>May 12, 2026<\/strong>. The decision follows completion of an <strong>equity adjustment<\/strong> that reduces Allogene&#8217;s stake in Overland Therapeutics to approximately <strong>3% on a fully diluted basis<\/strong>, transitioning the relationship from integrated strategic partnership to pure financial investment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Allogene Therapeutics, Inc. (US) and Overland Pharmaceuticals (US\/China)<\/td><\/tr><tr><td><strong>Original JV Formation<\/strong><\/td><td>December 2020 \u2013 Allogene Overland Biopharm<\/td><\/tr><tr><td><strong>Termination Date<\/strong><\/td><td>May 12, 2026<\/td><\/tr><tr><td><strong>Geographic Scope<\/strong><\/td><td>Greater China, Taiwan, South Korea, Singapore<\/td><\/tr><tr><td><strong>Assets Affected<\/strong><\/td><td>Four allogeneic CAR-T programs (BCMA, CD70, FLT3, DLL3 targets)<\/td><\/tr><tr><td><strong>Post-Transaction Equity<\/strong><\/td><td>~3% ownership in Overland Therapeutics (fully diluted)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-partnership-background\">Strategic Partnership Background<\/h2>\n\n\n\n<p>The <strong>Allogene Overland Biopharm joint venture<\/strong>, established in December 2020, granted <strong>exclusive development and commercialization rights<\/strong> for four <strong>chimeric antigen receptor (CAR)-T therapies<\/strong> targeting:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>BCMA<\/strong> \u2013 Multiple myeloma and other plasma cell disorders<\/li>\n\n\n\n<li><strong>CD70<\/strong> \u2013 Renal cell carcinoma and hematological malignancies<\/li>\n\n\n\n<li><strong>FLT3<\/strong> \u2013 Acute myeloid leukemia (AML)<\/li>\n\n\n\n<li><strong>DLL3<\/strong> \u2013 Small cell lung cancer and neuroendocrine tumors<\/li>\n<\/ul>\n\n\n\n<p>The partnership represented Allogene&#8217;s primary vehicle for <strong>Asian market access<\/strong> in the rapidly evolving allogeneic CAR-T landscape, leveraging Overland&#8217;s regional regulatory expertise and commercial infrastructure.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-rationale-amp-industry-context\">Rationale &amp; Industry Context<\/h2>\n\n\n\n<p>The termination reflects broader <strong>industry dynamics<\/strong> in the global allogeneic CAR-T development landscape:<\/p>\n\n\n\n<p><strong>Market Challenges:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Intensifying competition from autologous CAR-T therapies with established commercial success<\/li>\n\n\n\n<li>Regulatory complexity and extended approval timelines in Asian markets<\/li>\n\n\n\n<li>Capital constraints affecting development timelines for multiple parallel programs<\/li>\n\n\n\n<li>Evolving reimbursement environment for high-cost cell therapies in key Asian markets<\/li>\n<\/ul>\n\n\n\n<p><strong>Strategic Repositioning:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Allogene&#8217;s focus shift toward core US\/EU markets and lead programs<\/li>\n\n\n\n<li>Resource reallocation to prioritize clinical-stage assets with near-term commercial potential<\/li>\n\n\n\n<li>Risk mitigation in light of competitive pressures from Chinese domestic CAR-T developers<\/li>\n\n\n\n<li>Streamlined portfolio management amid challenging biotech financing environment<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-amp-operational-implications\">Financial &amp; Operational Implications<\/h2>\n\n\n\n<p><strong>For Allogene Therapeutics:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Reduced capital commitments<\/strong> to Asian development programs<\/li>\n\n\n\n<li><strong>Simplified operational structure<\/strong> with elimination of JV management overhead<\/li>\n\n\n\n<li><strong>Preserved financial exposure<\/strong> through retained 3% equity stake<\/li>\n\n\n\n<li><strong>Enhanced focus<\/strong> on proprietary allogeneic platform and lead indications<\/li>\n<\/ul>\n\n\n\n<p><strong>For Overland Pharmaceuticals:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Full control<\/strong> over regional CAR-T development strategy and timelines<\/li>\n\n\n\n<li><strong>Elimination of profit-sharing obligations<\/strong> for successful commercial products<\/li>\n\n\n\n<li><strong>Increased funding responsibility<\/strong> for continued program advancement<\/li>\n\n\n\n<li><strong>Opportunity to pursue alternative partnerships<\/strong> or independent development paths<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape-impact\">Competitive Landscape Impact<\/h2>\n\n\n\n<p>The dissolution of this cross-border collaboration highlights the <strong>evolving risk-reward calculus<\/strong> for Western cell therapy companies in Asian markets:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Chinese domestic players<\/strong> have accelerated their own CAR-T development programs with strong government support<\/li>\n\n\n\n<li><strong>Regulatory harmonization challenges<\/strong> between US FDA, EMA, and Asian agencies create development inefficiencies<\/li>\n\n\n\n<li><strong>Pricing pressure<\/strong> in cost-sensitive Asian healthcare systems affects commercial viability projections<\/li>\n\n\n\n<li><strong>Technology transfer concerns<\/strong> and intellectual property protection remain persistent barriers<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-outlook\">Strategic Outlook<\/h2>\n\n\n\n<p>This strategic retreat represents a <strong>significant pivot<\/strong> in Allogene&#8217;s global expansion strategy, suggesting:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Increased selectivity in international partnership formation<\/li>\n\n\n\n<li>Greater emphasis on markets with clearer regulatory pathways and reimbursement frameworks<\/li>\n\n\n\n<li>Potential consolidation of allogeneic CAR-T development efforts around fewer, higher-priority indications<\/li>\n\n\n\n<li>Continued evaluation of alternative market access strategies for Asian territories<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding strategic partnerships, business operations, and market positioning. Actual results may differ due to risks including competitive dynamics, regulatory developments, and strategic execution.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Allogene Therapeutics, Inc. (NASDAQ: ALLO) announced the termination of its strategic collaboration with Overland Pharmaceuticals&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[3469,21,77,3470,2694],"class_list":["post-65563","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-allogene-therapeutics","tag-car-t","tag-cell-therapy","tag-nasdaq-allo","tag-overland-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals \u2013 Strategic Retreat from Allogeneic Cell Therapy Market in Asia - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Allogene Therapeutics, Inc. (NASDAQ: ALLO) announced the termination of its strategic collaboration with Overland Pharmaceuticals on cell therapy development across key Asian markets, effective May 12, 2026. The decision follows completion of an equity adjustment that reduces Allogene&#039;s stake in Overland Therapeutics to approximately 3% on a fully diluted basis, transitioning the relationship from integrated strategic partnership to pure financial investment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65563\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals \u2013 Strategic Retreat from Allogeneic Cell Therapy Market in Asia\" \/>\n<meta property=\"og:description\" content=\"Allogene Therapeutics, Inc. (NASDAQ: ALLO) announced the termination of its strategic collaboration with Overland Pharmaceuticals on cell therapy development across key Asian markets, effective May 12, 2026. The decision follows completion of an equity adjustment that reduces Allogene&#039;s stake in Overland Therapeutics to approximately 3% on a fully diluted basis, transitioning the relationship from integrated strategic partnership to pure financial investment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65563\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-18T06:50:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-18T06:50:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65563#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65563\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals \u2013 Strategic Retreat from Allogeneic Cell Therapy Market in Asia\",\"datePublished\":\"2026-05-18T06:50:34+00:00\",\"dateModified\":\"2026-05-18T06:50:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65563\"},\"wordCount\":547,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Allogene Therapeutics\",\"CAR-T\",\"Cell-therapy\",\"NASDAQ: ALLO\",\"Overland Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65563#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65563\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65563\",\"name\":\"Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals \u2013 Strategic Retreat from Allogeneic Cell Therapy Market in Asia - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-18T06:50:34+00:00\",\"dateModified\":\"2026-05-18T06:50:35+00:00\",\"description\":\"Allogene Therapeutics, Inc. (NASDAQ: ALLO) announced the termination of its strategic collaboration with Overland Pharmaceuticals on cell therapy development across key Asian markets, effective May 12, 2026. The decision follows completion of an equity adjustment that reduces Allogene's stake in Overland Therapeutics to approximately 3% on a fully diluted basis, transitioning the relationship from integrated strategic partnership to pure financial investment.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65563#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65563\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65563#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals \u2013 Strategic Retreat from Allogeneic Cell Therapy Market in Asia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals \u2013 Strategic Retreat from Allogeneic Cell Therapy Market in Asia - Insight, China&#039;s Pharmaceutical Industry","description":"Allogene Therapeutics, Inc. (NASDAQ: ALLO) announced the termination of its strategic collaboration with Overland Pharmaceuticals on cell therapy development across key Asian markets, effective May 12, 2026. The decision follows completion of an equity adjustment that reduces Allogene's stake in Overland Therapeutics to approximately 3% on a fully diluted basis, transitioning the relationship from integrated strategic partnership to pure financial investment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65563","og_locale":"en_US","og_type":"article","og_title":"Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals \u2013 Strategic Retreat from Allogeneic Cell Therapy Market in Asia","og_description":"Allogene Therapeutics, Inc. (NASDAQ: ALLO) announced the termination of its strategic collaboration with Overland Pharmaceuticals on cell therapy development across key Asian markets, effective May 12, 2026. The decision follows completion of an equity adjustment that reduces Allogene's stake in Overland Therapeutics to approximately 3% on a fully diluted basis, transitioning the relationship from integrated strategic partnership to pure financial investment.","og_url":"https:\/\/flcube.com\/?p=65563","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-18T06:50:34+00:00","article_modified_time":"2026-05-18T06:50:35+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65563#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65563"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals \u2013 Strategic Retreat from Allogeneic Cell Therapy Market in Asia","datePublished":"2026-05-18T06:50:34+00:00","dateModified":"2026-05-18T06:50:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65563"},"wordCount":547,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Allogene Therapeutics","CAR-T","Cell-therapy","NASDAQ: ALLO","Overland Pharmaceuticals"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65563#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65563","url":"https:\/\/flcube.com\/?p=65563","name":"Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals \u2013 Strategic Retreat from Allogeneic Cell Therapy Market in Asia - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-18T06:50:34+00:00","dateModified":"2026-05-18T06:50:35+00:00","description":"Allogene Therapeutics, Inc. (NASDAQ: ALLO) announced the termination of its strategic collaboration with Overland Pharmaceuticals on cell therapy development across key Asian markets, effective May 12, 2026. The decision follows completion of an equity adjustment that reduces Allogene's stake in Overland Therapeutics to approximately 3% on a fully diluted basis, transitioning the relationship from integrated strategic partnership to pure financial investment.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65563#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65563"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65563#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals \u2013 Strategic Retreat from Allogeneic Cell Therapy Market in Asia"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65563","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65563"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65563\/revisions"}],"predecessor-version":[{"id":65564,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65563\/revisions\/65564"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65563"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65563"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65563"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}